Cannabis Bioscience International Holdings, Inc. (CBIH)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cannabis Bioscience International Holdings, Inc. (CBIH) trades at $0.00 with AI Score 49/100 (Grade C). Cannabis Bioscience International Holdings, Inc. Market cap: $3.49M, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for CBIH: CBIH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CBIH against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CBIH: the 1 perspectives are evenly split.
How is this calculated? →Cannabis Bioscience International Holdings, Inc. (CBIH) Healthcare & Pipeline Overview
Cannabis Bioscience International Holdings, Inc. (CBIH) is a pioneering educational provider in the medical cannabis sector, specializing in clinical trials and therapeutic services, with a focus on enhancing the understanding and application of cannabis-based treatments.
What Is the Investment Thesis for CBIH?
Cannabis Bioscience International Holdings, Inc. is positioned to benefit from the expanding medical cannabis market, which is projected to grow significantly as more regions legalize cannabis for therapeutic use. The company’s focus on educational services and clinical trials provides a unique value proposition in a sector that is increasingly reliant on scientific validation. With a profit margin currently at -416.8% and a gross margin of -0.1%, the company faces financial challenges that need addressing. However, the growing awareness of cannabis benefits and the demand for education in this field could drive revenue growth in the coming years. By enhancing its service offerings and expanding its geographic reach, CBIH aims to improve its financial metrics and establish a stronger market presence.
Based on FMP financials and quantitative analysis
CBIH Key Highlights
- Market Cap: $0.00B, indicating a need for growth and potential investment opportunities.
- Profit Margin: -416.8%, highlighting current financial challenges that CBIH must overcome.
- Gross Margin: -0.1%, suggesting a need for operational improvements to achieve profitability.
- Beta: 1.65, indicating higher volatility compared to the market, which may reflect investor sentiment towards the cannabis sector.
- No dividend yield, as the company is focused on growth and reinvestment rather than returning capital to shareholders.
Who Are CBIH's Competitors?
CBIH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ACB Aurora Cannabis Inc. | $2.77 | -2.50% | $171.52M | 55 |
| CRON Cronos Group Inc. | $2.76 | -3.50% | $1.03B | 62 |
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CBIH's Key Strengths?
- Specialization in medical cannabis education and clinical trials.
- Established infrastructure with a fertility and sleep center.
- Strong potential for growth in a rapidly evolving market.
What Are CBIH's Weaknesses?
- Limited workforce of only two employees.
- Current negative profit margins indicating financial instability.
- Dependence on the evolving regulatory landscape for cannabis.
What Could Drive CBIH Stock Higher?
- Expansion of online educational offerings to attract more students in the medical cannabis field.
- Development of clinical trials to validate cannabis treatments for sleep disorders and infertility.
- Potential partnerships with healthcare providers to enhance service delivery and credibility.
- Increasing legalization of medical cannabis in various regions, creating a larger market for CBIH's services.
What Are the Key Risks for CBIH?
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Regulatory changes could impact the operational landscape for medical cannabis education and clinical trials.
- Financial instability due to negative profit margins may limit growth opportunities.
- Competition from larger, more established cannabis companies could hinder market penetration.
What Are the Growth Opportunities for CBIH?
- Growth opportunity 1: The global medical cannabis market is expected to grow at a CAGR of 26.7% from 2021 to 2028, providing CBIH with a significant opportunity to expand its educational services and clinical trial offerings, particularly in regions where cannabis is becoming legalized for medical use.
- Growth opportunity 2: The rise in sleep disorders and infertility issues presents a growing market for CBIH's therapeutic services. With an increasing number of patients seeking alternative treatments, the company can leverage its fertility and sleep center to capture a share of this expanding market.
- Growth opportunity 3: Advancements in online education and digital publishing allow CBIH to reach a broader audience, enhancing its Pharmacology University offerings. By integrating innovative technologies into its curriculum, the company can attract more students and professionals interested in cannabis education.
- Growth opportunity 4: Strategic partnerships with healthcare providers and research institutions can enhance CBIH's clinical trial capabilities. Collaborating with established entities in the medical field can increase credibility and facilitate access to funding and resources for research initiatives.
- Growth opportunity 5: Expanding into international markets, particularly in Latin America where cannabis regulations are evolving, presents a lucrative opportunity. CBIH can establish its educational systems and therapeutic services in these emerging markets, capitalizing on the increasing demand for cannabis-related knowledge and treatment options.
What Opportunities Does CBIH Have?
- Expanding global market for medical cannabis education.
- Increasing demand for alternative treatments for sleep and infertility.
- Potential for strategic partnerships to enhance service offerings.
What Threats Does CBIH Face?
- Intense competition from established cannabis companies.
- Regulatory changes that could impact operations.
- Market volatility associated with the cannabis sector.
What Are CBIH's Competitive Advantages?
- Unique focus on educational systems within the medical cannabis sector.
- Established presence in Houston, Texas, a growing market for cannabis services.
- Access to clinical trial capabilities that enhance credibility.
- Specialization in therapeutic areas like sleep disorders and infertility.
- Strong emphasis on digital education and online reach.
What Does CBIH Do?
Cannabis Bioscience International Holdings, Inc., originally founded as China Infrastructure Construction Corp. in 2003, is headquartered in Houston, Texas. The company has evolved to focus on providing educational systems centered around medical cannabis, targeting markets in the United States, Latin America, and globally through online platforms. CBIH offers a diverse range of services, including clinical trials and therapeutic support for sleep disorders and infertility, facilitated through its specialized fertility and sleep center located in Houston. Additionally, the company operates the Pharmacology University, which provides education, consulting, digital publishing, marketing, and franchising in relation to medical cannabis. This strategic positioning allows CBIH to leverage its expertise in the therapeutic applications of cannabis while addressing the growing demand for education and awareness in this emerging field. With a small workforce of just two employees, the company is poised to capitalize on the expanding medical cannabis market, which is experiencing significant growth driven by increasing legalization and acceptance of cannabis-based treatments across various jurisdictions.
What Products and Services Does CBIH Offer?
- Provide educational systems focused on medical cannabis.
- Offer clinical trial services in therapeutic areas.
- Operate a fertility and sleep center in Houston, Texas.
- Deliver consulting and marketing services related to medical cannabis.
- Facilitate online education through Pharmacology University.
- Engage in digital publishing to disseminate cannabis-related knowledge.
How Does CBIH Make Money?
- Generate revenue through educational services and consulting.
- Conduct clinical trials and therapeutic services for patients.
- Leverage digital publishing and marketing to reach broader audiences.
- Offer franchising opportunities related to medical cannabis education.
- Provide specialized services through the fertility and sleep center.
What Industry Does CBIH Operate In?
The drug manufacturing industry, particularly in the specialty and generic sectors, is undergoing rapid transformation due to the increasing acceptance of medical cannabis. With the global medical cannabis market projected to reach $56.7 billion by 2025, companies like Cannabis Bioscience International Holdings, Inc. are well-positioned to capitalize on this trend. The competitive landscape includes numerous players focusing on cannabis-based therapies, but CBIH's emphasis on education and clinical trials differentiates it from traditional manufacturers. As the industry evolves, regulatory changes and increased consumer awareness are expected to drive growth and innovation.
Who Are CBIH's Key Customers?
- Healthcare professionals seeking cannabis education.
- Patients looking for alternative treatments for sleep disorders and infertility.
- Institutions interested in cannabis-related research and education.
- Franchise partners in the medical cannabis sector.
- Individuals pursuing careers in the medical cannabis industry.
Company Profile
Cannabis Bioscience International Holdings, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Houston, US. The company is led by CEO Dante Picazo. CBIH has traded publicly since 2023.
ROE 39%Key Financial Metrics
Return on equity for Cannabis Bioscience International Holdings, Inc. stands at 39.3%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -7.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -14.8%, the inverse of the P/E and a quick read on earnings relative to price.
CBIH Valuation & Market Position
With a $3.49M market cap, Cannabis Bioscience International Holdings, Inc. sits in the micro-cap segment of the market. Relative to its peer group, CBIH's quantitative score of 49/100 is below the peer average of 64/100.
Quarterly Financial Performance: Cannabis Bioscience International Holdings, Inc.
Revenue for Cannabis Bioscience International Holdings, Inc. came in at $11K during Q1 2026, a 79.0% contraction versus the preceding quarter. The company recorded a net loss of $104K, with diluted EPS of $0.00. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, CBIH averaged $-0.01 in diluted EPS.
F-Score 3/9Financial Health
Cannabis Bioscience International Holdings, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
CBIH Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Specialization in medical cannabis education and clinical trials.
- Established infrastructure with a fertility and sleep center.
- Strong potential for growth in a rapidly evolving market.
- Upcoming: Expansion of online educational offerings to attract more students in the medical cannabis field.
Bear Case
- Limited workforce of only two employees.
- Current negative profit margins indicating financial instability.
- Dependence on the evolving regulatory landscape for cannabis.
- Potential: Regulatory changes could impact the operational landscape for medical cannabis education and clinical trials.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $11,205 | -$103,933 | $0.00 |
| Q4 2025 | $53,266 | -$116,966 | $0.00 |
| Q3 2025 | $24,200 | -$82,645 | -$0.01 |
| Q2 2025 | $34,956 | -$211,744 | -$0.02 |
Based on FMP financials and quantitative analysis
CBIH Latest News
-
CBIH Advances Strategic Pathway to Bring VitaCookies' Science-Driven Functional Wellness Platform to Texas Consumers
feeds.newsfilecorp.com · Jun 8, 2026
-
CBIH Completes Cannabinoid-Based Melanoma Patent Application Program Focused on Cannabinoid Science and Epigenetic Regulation
feeds.newsfilecorp.com · Jun 1, 2026
CBIH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CBIH.
Price Targets
Wall Street price target analysis for CBIH.
CBIH MoonshotScore
What does this score mean?
The MoonshotScore rates CBIH's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
CBIH Advances Strategic Pathway to Bring VitaCookies' Science-Driven Functional Wellness Platform to Texas Consumers
CBIH Completes Cannabinoid-Based Melanoma Patent Application Program Focused on Cannabinoid Science and Epigenetic Regulation
Leadership: Dante Picazo
CEO
Dante Picazo has been leading Cannabis Bioscience International Holdings, Inc. since its inception in 2003. With a focus on the medical cannabis sector, he has developed expertise in educational systems and clinical trials. His leadership has been pivotal in navigating the challenges of a rapidly evolving industry.
Track Record: Under Dante Picazo's leadership, the company has established a unique position in the medical cannabis education space, expanding its offerings and enhancing its credibility in the market. His strategic decisions have aimed to align CBIH with emerging trends in cannabis therapeutics.
CBIH OTC Market Information
The OTC Other tier represents companies that do not meet the listing requirements of major exchanges like NYSE or NASDAQ. These stocks typically have lower trading volumes and may lack comprehensive financial disclosures, making them riskier investments compared to more established public companies.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosures may hinder transparency and investor confidence.
- Lower liquidity compared to stocks listed on major exchanges can lead to price volatility.
- Regulatory risks associated with the cannabis industry can impact operations and stock performance.
- Verify the company's financial health and operational metrics.
- Assess the management team's experience and track record.
- Research the regulatory environment surrounding cannabis in target markets.
- Evaluate the competitive landscape and market positioning.
- Examine the company's growth strategy and potential risks.
- Established presence since 2003, indicating longevity in the market.
- Focus on education and clinical trials adds credibility to its business model.
- Engagement in therapeutic areas aligns with growing healthcare trends.
CBIH Healthcare Stock FAQ
What does Cannabis Bioscience International Holdings, Inc. do?
Cannabis Bioscience International Holdings, Inc. focuses on providing educational systems related to medical cannabis. The company offers services in clinical trials and therapeutic areas, particularly sleep disorders and infertility, through its fertility and sleep center in Houston, Texas. Additionally, CBIH operates the Pharmacology University, which provides education, consulting, and marketing services in the medical cannabis sector.
What are the main risks for CBIH?
The primary risks for Cannabis Bioscience International Holdings, Inc. include regulatory changes that could affect the operational landscape of the medical cannabis industry. Additionally, the company faces financial instability, as indicated by its negative profit margins, which may limit its growth potential. Furthermore, competition from larger, well-established cannabis companies poses a significant threat to market penetration and overall business success.
How does Cannabis Bioscience International Holdings, Inc. navigate regulatory approval processes?
Cannabis Bioscience International Holdings, Inc. navigates regulatory approval processes by staying informed about the evolving legal landscape surrounding medical cannabis. The company focuses on compliance with local and federal regulations, which is crucial for conducting clinical trials and providing educational services. By maintaining transparency and engaging with regulatory bodies, CBIH aims to ensure that its operations align with legal requirements, thus mitigating potential risks associated with regulatory changes.
What are the key factors to evaluate for CBIH?
Cannabis Bioscience International Holdings, Inc. (CBIH) holds an AI score of 49/100 (low). Not financial advice.
How frequently does CBIH data refresh on this page?
CBIH prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CBIH's recent stock price performance?
Cannabis Bioscience International Holdings, Inc. (CBIH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialization in medical cannabis education and clinical trials. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CBIH overvalued or undervalued right now?
Valuing Cannabis Bioscience International Holdings, Inc. (CBIH) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CBIH?
Before investing in Cannabis Bioscience International Holdings, Inc. (CBIH), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The company's financial disclosures are currently unknown, which may limit comprehensive analysis.